Drug Profile
MT 0169
Alternative Names: MT-0169; TAK-169Latest Information Update: 22 Apr 2024
Price :
$50
*
At a glance
- Originator Molecular Templates; Takeda Oncology
- Class Antineoplastics; Bacterial toxins; Immunoglobulin fragments; Immunotoxins; Recombinant fusion proteins
- Mechanism of Action Proteasome inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma
- Discontinued Multiple myeloma
Most Recent Events
- 22 Apr 2024 Molecular Templates plans an investigator sponsored phase I trial for Acute myeloid leukemia in mid 2024
- 19 Apr 2024 Discontinued - Phase-I for Multiple myeloma (Second-line therapy or greater) in USA (IV)
- 13 Dec 2023 Molecular Templates terminates a Phase-I clinical trials in Multiple Myeloma (Second-line therapy or greater) in USA (IV, Infusion) due to sparse enrollment (NCT04017130)